Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jerry Avorn

Showing results (1-10 of 436) with videos related to

Pageof 44
Sort By:
The New England Journal of Medicine|October 16, 2023
Wedding Websites, Free Speech, and Adverse Drug EffectsJerry Avorn
Pharmacoeconomics|January 22, 2005
The role of pharmacoepidemiology and pharmacoeconomics in promoting access and stimulating innovationJerry Avorn
The New England Journal of Medicine|June 6, 2008
Coagulation and adulteration--building on science and policy lessons from 1905Jerry Avorn
The New England Journal of Medicine|May 14, 2015
The $2.6 billion pill--methodologic and policy considerationsJerry Avorn
The New England Journal of Medicine|April 17, 2007
Paying for drug approvals--who's using whom?Jerry Avorn
Medgenmed : Medscape General Medicine|April 17, 2007
The marketplace can't give us the drug safety data we needJerry Avorn
Circulation|August 14, 2013
The promise of pharmacoepidemiology in helping clinicians assess drug riskJerry Avorn
JAMA Network Open|April 28, 2023
Surrogate Measures of Drug Efficacy-A Finger Pointing at the MoonJerry Avorn
American Journal of Epidemiology|October 10, 2024
Invited commentary on interventional pharmacoepidemiology: origins, current status, and future possibilitiesJerry Avorn
The New England Journal of Medicine|September 5, 2008
Drug warnings that can cause fits--communicating risks in a data-poor environmentJerry Avorn
Pageof 44

Showing results (1-10 of 436) with videos related to

Sort By:
Pageof 44
The New England Journal of Medicine|October 16, 2023
Wedding Websites, Free Speech, and Adverse Drug EffectsJerry Avorn
Pharmacoeconomics|January 22, 2005
The role of pharmacoepidemiology and pharmacoeconomics in promoting access and stimulating innovationJerry Avorn
The New England Journal of Medicine|June 6, 2008
Coagulation and adulteration--building on science and policy lessons from 1905Jerry Avorn
The New England Journal of Medicine|May 14, 2015
The $2.6 billion pill--methodologic and policy considerationsJerry Avorn
The New England Journal of Medicine|April 17, 2007
Paying for drug approvals--who's using whom?Jerry Avorn
Medgenmed : Medscape General Medicine|April 17, 2007
The marketplace can't give us the drug safety data we needJerry Avorn
Circulation|August 14, 2013
The promise of pharmacoepidemiology in helping clinicians assess drug riskJerry Avorn
JAMA Network Open|April 28, 2023
Surrogate Measures of Drug Efficacy-A Finger Pointing at the MoonJerry Avorn
American Journal of Epidemiology|October 10, 2024
Invited commentary on interventional pharmacoepidemiology: origins, current status, and future possibilitiesJerry Avorn
The New England Journal of Medicine|September 5, 2008
Drug warnings that can cause fits--communicating risks in a data-poor environmentJerry Avorn
Pageof 44